XTalks

MAY 26, 2023

Krystal Biotech’s Vyjuvek has been awarded US Food and Drug Administration (FDA) approval to make it the first topical gene therapy for the treatment of wounds in patients with the rare, often debilitating skin disease dystrophic epidermolysis bullosa (DEB). As a topical treatment, it is also the first readily redosable gene therapy.

Gene Therapy 97

Gene Therapy Gene Dermatology FDA Approval 97

Scienmag

AUGUST 14, 2020

Discovery could lead to new screening tests and potential treatments Credit: Cincinnati Children’s Two common variants in the KIF3A gene increase the risk of young children having a dysfunctional skin barrier and developing the skin condition atopic dermatitis.

Allergies 97

Allergies Gene Development Dermatology 97

XTalks

JANUARY 2, 2024

For instance, Vyjuvek , the first FDA-approved gene therapy for DEB, is priced at $24,250 per vial. a biotech company specializing in the development and commercialization of genetic medicines for rare diseases, announced FDA approval for Vyjuvek for the treatment of DEB.

FDA Approval 111

FDA Approval Gene Therapy Gene Trials 111

Pharmaceutical Technology

APRIL 13, 2023

Metabolic disorders are top therapy areas Analysis curated by GlobalData [5] shows the top three therapy areas for DCT adoption in the first quarter of 2022 were metabolic disorders, followed by central nervous system (CNS) and genetic disorders. However, there is still some use of remote patient monitoring technologies.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Dermatology 130

XTalks

SEPTEMBER 22, 2022

GPP occurs in individuals with specific gene variations as it is a genetic disease , and variations in the genes IL36RN and AP1S3 are known to cause it. The role of the IL-36 receptor was confirmed in loss-of-function mutation studies in the IL-36 receptor antagonist gene. Waldman Department of Dermatology.

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials Dermatology 52

XTalks

MAY 31, 2022

The precise cause of psoriasis is unknown, but risk factors include genetics and a family history of the condition, heavy alcohol consumption, stress, smoking and dry or cold weather. At Dermavant, we are committed to advancing novel, patient-focused innovation in immuno-dermatology. Clinical Trials of Vtama.

FDA Approval 98

FDA Approval Clinical Trials Clinical Trials Trials 98

Scienmag

OCTOBER 25, 2020

A new drug designed to work on cancers with an altered BRAF gene has shown promise in an early patient trial presented at the 32nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online. The BRAF gene is involved in telling healthy cells when to grow and form new cells, […].

Trials 41

Trials Gene Drugs Clinical Trials 41